G
Guangwei Luo
Publications - 4
Citations - 2932
Guangwei Luo is an academic researcher. The author has contributed to research in topics: Clinical endpoint & Placebo. The author has an hindex of 3, co-authored 3 publications receiving 2181 citations.
Papers
More filters
Journal ArticleDOI
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang,Yeming Wang,Dingyu Zhang,Guanhua Du,Ronghui Du,Jianping Zhao,Yang Jin,Shouzhi Fu,Ling Gao,Zhenshun Cheng,Qiaofa Lu,Yi Hu,Guangwei Luo,Ke Wang,Yang Lu,Huadong Li,Shuzhen Wang,Shunan Ruan,Chengqing Yang,Chunlin Mei,Yi Wang,Dan Ding,Feng Wu,Xin Tang,Xianzhi Ye,Yingchun Ye,Bing Liu,Jie Yang,Wen Yin,Aili Wang,Guohui Fan,Fei Zhou,Zhibo Liu,Xiaoying Gu,Jiuyang Xu,Lianhan Shang,Lianhan Shang,Yi Zhang,Lianjun Cao,Guo Tingting,Yan Wan,Hong Qin,Yushen Jiang,Thomas Jaki,Thomas Jaki,Frederick G. Hayden,Peter Horby,Bin Cao,Chen Wang +48 more
TL;DR: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
Journal ArticleDOI
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Yeming Wang,Fei Zhou,Dingyu Zhang,Jianping Zhao,Ronghui Du,Yi Hu,Zhenshun Cheng,Ling Gao,Yang Jin,Guangwei Luo,Shouzhi Fu,Qiaofa Lu,Guanhua Du,Ke Wang,Yang Lu,Guohui Fan,Yi Zhang,Ying Liu,Shunan Ruan,Wen Liu,Thomas Jaki,Frederick G. Hayden,Peter Horby,Bin Cao,Bin Cao,Chen Wang,Chen Wang +26 more
TL;DR: This is the first randomized, placebo-controlled trial in COVID-19, and one interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed.
Journal ArticleDOI
Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
TL;DR: The current understanding of the pathogenesis of IPF, the progress of research on the use of statins in IPF models and clinical trials, and its main molecular targets are summarized.
Journal ArticleDOI
Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease.
Tao Wang,Guangwei Luo,Yi Hu,Fajiu Li,Jing Ma,Jianmiao Wang,Peng Zuo,Weining Xiong,Xiansheng Liu,Jianping Zhao,Shengdao Xiong,Zhen-xiang Zhang,Chenghong Li,Su Zhao,Jiemin Sun,Yongjian Xu +15 more
TL;DR: Both tiotropium at 18 μg a day and doxofylline tablets at 0.2 g/day (two times a day) are effective and safe for the treatment of COPD.